Antiretroviral abacavir linked with cardiovascular events in REPRIEVE trial
MedPage Today highlights UC-led trial analysis
People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of the REPRIEVE trial presented by the University of Cincinnati's Carl Fichtenbaum, MD, at the International AIDS Conference.
MedPage Today highlighted the findings that past use of abacavir increased the risk of MACE by 50% and current use increased MACE risk by 42%.
"Hopefully, with newer antiretrovirals and longer-acting therapy, perhaps this will become less and less of a problem as we're able to shift away and use other things to control HIV replication," said Fichtenbaum, professor in the Division of Infectious Diseases in the UC College of Medicine.
"Since there are many other options available — certainly in high-income countries — I think we have to consider the fact that the most important thing is controlling HIV replication, but that where we can, it may be helpful to avoid the use of abacavir," Fichtenbaum continued.
Read the MedPage Today article.
U.S. Pharmacist also highlighted the research. Read the U.S. Pharmacist article.
Featured photo at top of illustration of cardiovascular system. Photo/magicmine/iStock.
Related Stories
Putting preschool into perspective
July 20, 2026
Preschool and childcare can be difficult to navigate for parents, as Spectrum News 1 Ohio recently reported. Waitlists are long, and factors like cost, location and transportation can limit options. According to a recent study published by The Annie E. Casey Foundation, only 41% of 3- to 4-year-olds in Ohio were enrolled in preschool between 2020 and 2024 — a 4% decrease from pre-pandemic numbers. For University of Cincinnati early childhood education faculty member Chad Nunamaker, that statistic has caveats.
Engineering magnets for a cleaner future
July 20, 2026
The United States is heavily reliant on imported rare-earth materials to make permanent magnets. Ugochukwu Philip Ochieze, materials science student at the University of Cincinnati, is studying how to use common materials to create permanent magnets, eliminating the need for expensive and scarce rare-earth materials. Pursuing his PhD, Ochieze was named Graduate Student Engineer of the Month by the College of Engineering and Applied Science.
Ticks that survive pesticides can withstand colder winters
July 17, 2026
Ticks that survive less-than-lethal doses of pesticide are able to withstand dangerous cold, which could help them expand their range farther north, according to researchers at the University of Cincinnati and the U.S. Department of Agriculture.